Genexine 
Welcome,         Profile    Billing    Logout  
 11 Products   1 Disease   11 Products   30 Trials   491 News 


1234567»
  • ||||||||||  Breyanzi (lisocabtagene maraleucel) / BMS, Hyleukin-7 (efineptakin alfa) / Genexine, NeoImmuneTech, Yescarta (axicabtagene ciloleucel) / Gilead
    New P1 trial:  NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Yescarta (clinicaltrials.gov) -  Jul 7, 2025   
    P1,  N=24, Not yet recruiting, 
  • ||||||||||  GX-G6 / Genexine
    Trial completion, Trial completion date, Trial primary completion date:  A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity (clinicaltrials.gov) -  May 14, 2025   
    P2,  N=314, Completed, 
    Moreover, the safety profile of efepoetin alfa was comparable to methoxy polyethylene glycol-epoetin beta. Active, not recruiting --> Completed | Trial completion date: Mar 2025 --> Oct 2024 | Trial primary completion date: Dec 2024 --> Sep 2024
  • ||||||||||  Hyleukin-7 (efineptakin alfa) / Genexine, NeoImmuneTech
    NT-I7 increases lymphocytes and enhances chemotherapy and immunotherapy efficacy in HNSCC (Section 35; Poster Board No: 6) -  Mar 25, 2025 - Abstract #AACR2025AACR_4476;    
    Active, not recruiting --> Completed | Trial completion date: Mar 2025 --> Oct 2024 | Trial primary completion date: Dec 2024 --> Sep 2024 NT-I7 effectively increases lymphocyte populations in HNSCC preclinical models that demonstrate tumor-associated lymphopenia, and enhances the efficacy of cisplatin and anti-PD-1 in HNSCC preclinical tumor models.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Hyleukin-7 (efineptakin alfa) / Genexine, NeoImmuneTech
    Trial completion date, Trial primary completion date, Tumor mutational burden:  Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma (clinicaltrials.gov) -  Dec 4, 2024   
    P2,  N=44, Recruiting, 
    Recruiting --> Active, not recruiting | N=70 --> 42 | Trial primary completion date: Jan 2032 --> Feb 2025 Trial completion date: Oct 2025 --> Oct 2028 | Trial primary completion date: Oct 2024 --> Oct 2027
  • ||||||||||  Hyleukin-7 (efineptakin alfa) / Genexine, NeoImmuneTech
    IL-7 stimulation remodels the tumor immune microenvironment in lung adenocarcinoma (Exhibit Halls AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_1406;    
    The mice received weekly treatments of either NT-I7 (efineptakin alfa, a recombinant human IL-7 agonist) or a vehicle control for 2 weeks...Through this spatial and molecular biology study, potential mechanisms underlying the enhancement of lymphocyte infiltration by IL-7 agonist therapy in lung cancer are unveiled, crucial for improving clinical efficacy of immunotherapy. Moreover, the upregulation of Cd274 in IL-7-treated mice suggests a potential synergy between IL-7 and PD-1/PD-L1 checkpoint blockade therapy.
  • ||||||||||  GX-G6 / Genexine
    Enrollment closed:  A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity (clinicaltrials.gov) -  Jul 15, 2024   
    P2,  N=300, Active, not recruiting, 
    Ethics Approval This trial obtained approval from MD Anderson IRB (2020-0008), Advarra IRB (IRB00000971), and Mary Crowley IRB (20 Not yet recruiting --> Active, not recruiting
  • ||||||||||  HyPoietin (epoetin alfa biosimilar) / GC Biopharma, Genexine, Fosun Pharma
    New P1 trial:  Clinical Trial of Efepoetin Alfa in Healthy Subjects (clinicaltrials.gov) -  Jul 7, 2024   
    P1,  N=40, Not yet recruiting, 
  • ||||||||||  Hyleukin-7 (efineptakin alfa) / Genexine, NeoImmuneTech
    Trial completion date, Trial primary completion date, IO biomarker:  NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery (clinicaltrials.gov) -  Jun 6, 2024   
    P1,  N=10, Recruiting, 
    Trial completion date: Apr 2027 --> Sep 2027 | Trial primary completion date: Jun 2025 --> Dec 2026 Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
  • ||||||||||  Hyleukin-7 (efineptakin alfa) / Genexine, NeoImmuneTech
    Journal, Tumor-infiltrating lymphocyte, PD(L)-1 Biomarker, IO biomarker:  IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T (Pubmed Central) -  May 22, 2024   
    Notably, TCE treatment has no major effect on tumor-reactive CD8 TILs. Our results suggest that rhIL-7-hyFc treatment promotes the antitumor efficacy of TCE immunotherapy by increasing TCE-sensitive bystander CD8 TILs in solid tumors.
  • ||||||||||  Hyleukin-7 (efineptakin alfa) / Genexine, NeoImmuneTech
    Expand and pull: A new treatment paradigm for glioblastoma using a long-acting recombinant interleukin-7 and oncolytic viral therapy. (Hall A; Poster Bd #: 342) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_3150;    
    Timing the oncolytic ZIKV injection with the NT-I7-induced peak expansion of peripheral CD8 T cells greatly increased tumor infiltration of cytotoxic T cells and improved survival in the immunotherapy resistant SB28 glioma model. This work suggests a new "expand and pull" approach for the treatment of highly immunosuppressive tumors such as GBM: priming the systemic immune system with NT-I7, followed by an oncolytic stimulus to draw them into the TME to engage and clear tumor cells.
  • ||||||||||  Hyleukin-7 (efineptakin alfa) / Genexine, NeoImmuneTech
    Enrollment closed, Trial completion date, Trial primary completion date:  KEYNOTE A60: NT-I7 (Efineptakin Alfa) in Combination with Pembrolizumab in Participants with Advanced Solid Tumors (clinicaltrials.gov) -  Mar 15, 2024   
    P1/2,  N=215, Active, not recruiting, 
    The integrated use of ELISA and AMS offers valuable insights for the development and optimization of ABT. Trial completion date: Jun 2024 --> Mar 2025 | Trial primary completion date: Jun 2024 --> Nov 2024 | Recruiting --> Active, not recruiting
  • ||||||||||  Hyleukin-7 (efineptakin alfa) / Genexine, NeoImmuneTech
    rhIL-7-hyFc (efineptakin-alfa, NT-I7) increases tumor-specific CD8+ T cells despite FOLFOX cytotoxicity effect (Section 4) -  Mar 5, 2024 - Abstract #AACR2024AACR_7009;    
    However, adding FOLFOX does not affect the NT-I7-driven increase of tumor-specific CD8+ T cells within the tumor. Taken together, our data demonstrate that FOLFOX does not compromise NT-I7's ability to increase tumor-specific T cells within the tumor and the combination enhances the anti-tumor response irrespective of the timing of NT-I7 administration.
  • ||||||||||  GX-19N / Genexine, Binex, GenNBio, PT Kalbe Farma
    Trial completion:  Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals (clinicaltrials.gov) -  Mar 1, 2024   
    P1,  N=30, Completed, 
    Taken together, our data demonstrate that FOLFOX does not compromise NT-I7's ability to increase tumor-specific T cells within the tumor and the combination enhances the anti-tumor response irrespective of the timing of NT-I7 administration. Active, not recruiting --> Completed
  • ||||||||||  Hyleukin-7 (efineptakin alfa) / Genexine, NeoImmuneTech
    Phase classification, Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy:  High-Risk Skin Cancers With Atezolizumab Plus NT-I7 (clinicaltrials.gov) -  Feb 22, 2024   
    P1/2,  N=31, Terminated, 
    Phase classification: P1b/2 --> P1/2 Phase classification: P1b/2a --> P1/2 | N=84 --> 31 | Trial completion date: May 2024 --> Aug 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2024 --> Aug 2023; Strategic decision by sponsor
  • ||||||||||  Hyleukin-7 (efineptakin alfa) / Genexine, NeoImmuneTech
    Phase classification, CAR T-Cell Therapy:  Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy (clinicaltrials.gov) -  Feb 21, 2024   
    P1,  N=57, Recruiting, 
    Phase classification: P1b/2a --> P1/2 | N=84 --> 31 | Trial completion date: May 2024 --> Aug 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2024 --> Aug 2023; Strategic decision by sponsor Phase classification: P1b --> P1
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Hyleukin-7 (efineptakin alfa) / Genexine, NeoImmuneTech
    Enrollment closed, Trial completion date, Trial primary completion date:  Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors (clinicaltrials.gov) -  Jan 31, 2024   
    P2,  N=133, Active, not recruiting, 
    Phase classification: P1b --> P1 Recruiting --> Active, not recruiting | Trial completion date: Feb 2024 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Jun 2024
  • ||||||||||  Hyleukin-7 (efineptakin alfa) / Genexine, NeoImmuneTech
    Trial termination:  NT-I7 for Kaposi Sarcoma in Patients With or Without HIV (clinicaltrials.gov) -  Dec 26, 2023   
    P1,  N=8, Terminated, 
    Trial completion date: Jan 2030 --> Jan 2032 | Trial primary completion date: Jan 2030 --> Jan 2032 Active, not recruiting --> Terminated; Terminated due to end of funding
  • ||||||||||  HyPoietin (epoetin alfa biosimilar) / GC Biopharma, Genexine, Fosun Pharma
    Trial completion, Trial completion date:  A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient (clinicaltrials.gov) -  Dec 22, 2023   
    P3,  N=391, Completed, 
    Active, not recruiting --> Terminated; Terminated due to end of funding Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Jun 2023
  • ||||||||||  Hyleukin-7 (efineptakin alfa) / Genexine, NeoImmuneTech, UCART19 / Allogene Therap, Servier
    Journal:  An "off-the-shelf" CD2 universal CAR-T therapy for T-cell malignancies. (Pubmed Central) -  Nov 29, 2023   
    Treatment with rhIL-7-hyFc prolonged UCART2 persistence and increased survival in both the tumor re-challenge model and primary patient T-ALL model in vivo. Together, these data suggest that allogeneic fratricide-resistant UCART2, in combination with rhIL-7-hyFc, could be a suitable approach for treating T-cell malignancies.